Zhejiang-based holding company classified under health care/biotechnology; specific business segments not established from available knowledge.
Zhejiang-based holding company classified under health care/biotechnology; specific business segments not established from available knowledge.
Moat: none
Headquarters: Zhejiang, China · Employees: 1,046
Size Zhejiang Hengtong (600226.SS) is a China Health Care company (Biotechnology) with a market value of $1.64B, the 1402nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.88 on 18 Nov 2026.
Performance Over six months the shares fell 31.2%, against -3.7% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth Revenue grew 71.0% over the last twelve months (peer median +19.3%); the operating margin is -0.2% (peer median -18.1%).
Valuation It trades at 27.6× forward earnings against a peer median of 22.6× (4th most expensive of 8).
Capital Return on invested capital runs 6.3 points below its cost of capital (7.8% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.88B | CN¥1.85B | CN¥1.33B | CN¥646M | CN¥602M |
| Revenue growth | — | +40% | +105% | +7% | — |
| Gross profit | CN¥336M | CN¥111M | CN¥131M | CN¥128M | CN¥70.3M |
| EBITDA | n/a | CN¥102M | CN¥88.6M | CN¥59.3M | -CN¥52.8M |
| Net income | CN¥145M | CN¥201M | CN¥189M | CN¥166M | CN¥482M |
| Free cash flow | -CN¥210M | -CN¥445M | -CN¥5.69M | -CN¥406M | -CN¥155M |
| Capital expenditure | CN¥83.7M | CN¥297M | CN¥132M | CN¥396M | CN¥257M |
| Total debt | CN¥2.20B | CN¥1.03B | CN¥571M | CN¥320M | CN¥116M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600226.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.3% | -7.5% | 6th lowest of 20 |
| 6-month return | -31.2% | -3.7% | 4th lowest of 19 |
| Distance from 52-week high | -67.6% | -39.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | +71.0% | +19.3% | 5th highest of 19 |
| Operating margin | -0.2% | -18.1% | 10th highest of 19 |
| Forward P/E | 27.6× | 22.6× | 4th most expensive of 8 |
| ROIC minus cost of capital | -6.3 pp | -4.0 pp | 7th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Hengtong 600226.SS | China | $1.64B | -31% | +71% | 0% | 27.6× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 7.5× | -7.6% | +33.5% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 22.6× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 73.2× | 33.2% | +16.8% |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | n/a | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 52.1× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% | +15.0% |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | n/a | n/a | n/a |
| Stoke Therapeutics STOK | United States | $1.75B | -12% | -86% | -913% | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 7.3× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $1.76B | -5% | +56% | -725% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $1.78B | +39% | +25% | 22% | 51.9× | 33.0% | +24.8% |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |